Cytek Biosciences Inc (CTKB)

Currency in USD
4.46
-0.10(-2.19%)
Closed·
4.42-0.04(-0.90%)
·
Earnings results expected in 9 days
CTKB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.444.62
52 wk Range
3.286.18
Key Statistics
Prev. Close
4.46
Open
4.6
Day's Range
4.44-4.62
52 wk Range
3.28-6.18
Volume
597.21K
Average Volume (3m)
1.4M
1-Year Change
20.8672%
Book Value / Share
2.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CTKB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.69
Upside
+27.52%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Cytek Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.69
(+27.52% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stephens
Buy4.75+6.50%5.50MaintainMay 13, 2026
Morgan Stanley
Hold5.50+23.32%6.00MaintainMay 12, 2026
Morgan Stanley
Hold6.00+34.53%-New CoverageDec 02, 2025
Piper Sandler
Buy7.50+68.16%8.00MaintainNov 11, 2025

Cytek Biosciences Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue rose 6% YoY to $44.1M, slightly beating forecast; EPS loss of $0.15 missed estimate of $0.10 by 50%, stock fell 6.68% after-hours
  • U.S. market drove growth with 32% YoY increase; gross margin compressed to 48% from 49% prior year amid rising costs
  • Operating expenses jumped 13% to $39.7M due to higher legal and administrative costs, pressuring profitability despite revenue gains
  • Company maintains $262.2M cash position; projects FY2026 revenue of $208M and FY2027 revenue of $224.95M
  • Management focuses on Aurora Evo system expansion and strategic reorganization to align operations with customer needs and accelerate growth
Last Updated: 2026-05-14, 03:52 a/m
Read Full Transcript

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-0.15 / -0.10
Revenue / Forecast
44.1M / 43.95M
EPS Revisions
Last 90 days

CTKB Income Statement

Compare CTKB to Peers and Sector

Metrics to compare
CTKB
Peers
Sector
Relationship
P/E Ratio
−7.8x−1.7x−0.4x
PEG Ratio
0.01−0.130.00
Price/Book
1.8x5.6x2.6x
Price / LTM Sales
2.8x7.1x2.9x
Upside (Analyst Target)
17.7%11.5%58.0%
Fair Value Upside
Unlock16.4%9.5%Unlock

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
29.03M22.48%129.47M
Other Institutional Investors
64.01M49.57%285.48M
Public Companies & Retail Investors
36.10M27.96%161.02M
Total
129.14M100.00%575.98M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.25%9,356,55141,730
Millennium Management LLC6.10%7,872,90035,113

People Also Watch

83.16
HLNE
+2.48%
13.34
WNC
+0.30%
56.250
IDR
+5.42%
172.99
ENSG
+3.27%
94.50
BRC
+0.88%

FAQ

What Is the Cytek Biosciences (CTKB) Stock Price Today?

The Cytek Biosciences stock price today is 4.46 USD.

What Stock Exchange Does Cytek Biosciences Trade On?

Cytek Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cytek Biosciences?

The stock symbol for Cytek Biosciences is "CTKB."

What Is the Cytek Biosciences Market Cap?

As of today, Cytek Biosciences market cap is 575.98M USD.

What Is Cytek Biosciences's Earnings Per Share (TTM)?

The Cytek Biosciences EPS (TTM) is -0.58.

When Is the Next Cytek Biosciences Earnings Date?

Cytek Biosciences will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is CTKB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cytek Biosciences Stock Split?

Cytek Biosciences has split 0 times.

How Many Employees Does Cytek Biosciences Have?

Cytek Biosciences has 678 employees.

What is the current trading status of Cytek Biosciences (CTKB)?

As of Jul 27, 2026, Cytek Biosciences (CTKB) is trading at a price of 4.46 USD, with a previous close of 4.46 USD. The stock has fluctuated within a day range of 4.44 USD to 4.62 USD, while its 52-week range spans from 3.28 USD to 6.18 USD.

What Is Cytek Biosciences (CTKB) Price Target According to Analysts?

The average 12-month price target for Cytek Biosciences is 5.69 USD, with a high estimate of 7.5 USD and a low estimate of 4.75 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +27.52% Upside potential.

What Is the CTKB Premarket Price?

CTKB's last pre-market stock price is 4.42 USD. The pre-market share volume is 90.00, and the stock has decreased by -0.04, or -0.90%.

What Is the CTKB After Hours Price?

CTKB's last after hours stock price is 4.60 USD, the stock has decreased by 0.14, or 3.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.